Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Consensus Target Price from Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $27.00.

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th.

Insider Activity at Olema Pharmaceuticals

In related news, Director G. Walmsley Graham sold 700,761 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $6.75, for a total transaction of $4,730,136.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sean Bohen sold 52,328 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $490,313.36. Following the completion of the sale, the chief executive officer now owns 298,836 shares in the company, valued at $2,800,093.32. This represents a 14.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 773,797 shares of company stock worth $5,414,609. 19.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in shares of Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock valued at $102,000 after acquiring an additional 4,419 shares in the last quarter. Conway Capital Management Inc. bought a new position in shares of Olema Pharmaceuticals in the third quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. raised its stake in Olema Pharmaceuticals by 67.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after purchasing an additional 4,442 shares in the last quarter. Portland Investment Counsel Inc. bought a new stake in Olema Pharmaceuticals during the third quarter valued at approximately $143,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Olema Pharmaceuticals during the second quarter valued at approximately $145,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $5.66 on Thursday. The stock has a market capitalization of $324.32 million, a PE ratio of -2.58 and a beta of 2.05. Olema Pharmaceuticals has a one year low of $4.60 and a one year high of $16.77. The business’s fifty day moving average price is $7.65 and its 200-day moving average price is $10.81.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.